Correspondence 0001213900-25-014005 from Anbio Biotechnology (NNNN) (CIK 0001982708) (NNNN)
Anbio Biotechnology (NNNN) (CIK 0001982708)
Date: Feb. 14, 2025 · CIK: 0001982708 · Accession: 0001213900-25-014005
AI Filing Summary & Sentiment
File numbers found in text: 333-284106
Letter
Anbio Biotechnology
Wilhelm Gutbrod Str 21B, 60437,
Frankfurt am Main,
Germany
+49 16 0962 47281
February 14, 2025
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, D.C., 20549
Re: Anbio Biotechnology
Registration Statement on Form F-1, as amended (File No. 333-284106)
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Anbio Biotechnology hereby requests acceleration of the effectiveness of the above-referenced Registration Statement on Form F-1, as amended, so that such Registration Statement will become effective at 4:00 p.m., Eastern Time, on February 18, 2025, or as soon thereafter as practicable.
The Company understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
Very truly yours,
Anbio Biotechnology
Show Raw Text
CORRESP
1
filename1.htm
Anbio Biotechnology
Wilhelm Gutbrod Str 21B, 60437,
Frankfurt am Main,
Germany
+49 16 0962 47281
February 14, 2025
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, D.C., 20549
Re: Anbio Biotechnology
Registration Statement on Form F-1, as amended
(File No. 333-284106)
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
In accordance with Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended, Anbio Biotechnology hereby requests acceleration of
the effectiveness of the above-referenced Registration Statement on Form F-1, as amended, so that such Registration Statement will become
effective at 4:00 p.m., Eastern Time, on February 18, 2025, or as soon thereafter as practicable.
The Company understands that
the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the
fact that the Company is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the
securities specified in the Registration Statement.
Very truly yours,
Anbio Biotechnology
By:
/s/ Michael Lau
Name:
Michael Lau
Title:
Chief Executive Officer